Summary
An international prospective study evaluated a blood assay that combines a 10-microRNA signature with carbohydrate antigen 19-9 for detecting early pancreatic ductal adenocarcinoma. The composite PANXEON score showed 86.8% sensitivity for stage I–II disease in the testing cohort, but the researchers say larger prospective studies are still needed.
Researchers have developed and tested a blood-based assay intended to detect early pancreatic ductal adenocarcinoma (PDAC), a pancreatic cancer with poor outcomes. In an international, multicentre, prospective observational biomarker study published in Nature Medicine on 16 September 2026, the assay combined a 10-microRNA signature with carbohydrate antigen 19-9 (CA19-9) in a composite score called PANXEON.
In the study’s testing cohort, PANXEON detected stage I–II PDAC with 86.8% sensitivity. The researchers describe the result as a potential complement to existing approaches for early detection and say the assay requires further large-scale prospective evaluation.
Contents
How the blood assay works
The assay measures a pattern of 10 microRNAs in blood: hsa-miR-142-3p, hsa-miR-30c-5p, hsa-miR-335-5p, hsa-miR-340-5p, hsa-miR-200b-3p, hsa-miR-1260b, hsa-miR-145-3p, hsa-miR-145-5p, hsa-miR-429 and hsa-miR-200a-3p. MicroRNAs are short RNA molecules involved in regulating gene activity. Differences in their levels can provide a molecular signal associated with disease.
The researchers converted the combined microRNA pattern into a signature score and then integrated it with CA19-9, a blood marker used in the assessment of pancreatic disease. The resulting composite was named PANXEON, short for “PANcreatic cancer eXosome Early detectiON”.
The study used machine-learning analysis during development and evaluation of the signature. The aim was not simply to identify established cancer, but to assess whether a blood signal could distinguish early-stage PDAC from people without the disease and from individuals with other gastrointestinal cancers.
Study design and results
The study included 1,785 individuals with and without PDAC across four countries. It was prospective and observational, meaning that participants were assessed for biomarker performance rather than assigned to a treatment by the study.
The microRNA signature alone achieved an area under the receiver operating characteristic curve of 88.6% in the testing cohort. The area under the curve summarises how well a diagnostic model separates people with and without a condition across possible decision thresholds: 50% represents chance-level separation, while 100% represents perfect separation. The signature’s sensitivity for early-stage PDAC was 83.8% and it showed minimal cross-reactivity with other gastrointestinal cancers.
Adding CA19-9 increased the reported sensitivity for stage I–II PDAC to 86.8%. The false-positive rate was 3.2% among low-risk controls and 15.6% among high-risk controls in the testing cohort. These figures show that the assay’s performance varied according to the comparison group used for evaluation.
The researchers also examined people with high-risk pancreatic cysts. PANXEON showed potential for detecting high-grade dysplasia in this group, with a reported performance of 64.3%. High-grade dysplasia refers to severe abnormal cellular changes that can precede invasive cancer.
Treatment monitoring and next steps
In a separate cohort of 19 individuals, microRNA signature levels decreased during neoadjuvant chemotherapy, which is given before surgery, and after surgery. Levels increased before disease recurrence. These observations suggest that the signal changed alongside treatment and disease status in this small group, although the study was primarily designed to evaluate biomarker detection rather than establish a treatment-monitoring test.
The authors present PANXEON as a possible addition to existing strategies for identifying early PDAC, including assessment of people at elevated risk. The study was registered at ClinicalTrials.gov under NCT06388967. Its reported diagnostic results support continued evaluation, while the researchers specifically call for larger prospective studies before the assay’s role in routine early detection can be determined.